W. J. Kell

发表

The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison

R. Hills, N. Russell, A. Hunter, 2013, Leukemia.

Autologous Peripheral Blood Stem Cell Transplantation in First Remission Adult Acute Myeloid Leukaemia--An Intention to Treat Analysis and Comparison of Outcome Using a Predictive Model Based on the MRC AML10 Cohort

J. Chang, R. Chopra, A. Burnett, 2003, Hematology.

Photosensitivity and acute liver injury in myeloproliferative disorder secondary to late-onset protoporphyria caused by deletion of a ferrochelatase gene in hematopoietic cells.

Geraint T. Williams, M. Badminton, G. Elder, 2006, Blood.

Low dose Ara-C versus low Dose Ara-C and Tipifarnib: result of the UK NCRI AML16 "Pick a Winner" comparison [Abstract]

R. Hills, N. Russell, A. Burnett, 2008 .

in younger patients with acute myeloid leukemia ozogamicin with intensive chemotherapy in induction and consolidation A feasibility study of simultaneous administration of gemtuzumab

A. Rohatiner, R. Clark, R. Chopra, 2013 .

The Addition of Gemtuzumab Ozogamicin to Intensive Chemotherapy in Older Patients with AML Produces a Significant Improvement in Overall Survival: Results of the UK NCRI AML16 Randomized Trial

R. Hills, N. Russell, L. Kjeldsen, 2011 .

A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia

A. Rohatiner, R. Clark, A. Hunter, 2003 .

The Addition of Gemtuzumab Ozogamicin to Low Dose Ara-C Improves Remission Rates but Not Survival: Results of the UK LRF AML14 and NCRI AML16 “Pick a Winner” Comparison

R. Hills, N. Russell, A. Hunter, 2010 .

fit for intensive chemotherapy treatment for older patients with acute myeloid leukemia not considered A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line

R. Clark, M. Levis, D. Small, 2013 .

A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy.

Richard Clark, R. Clark, M. Levis, 2004, Blood.

The addition of gemtuzumab ozogamicin to induction chemotherapy for AML improves disease free survival without extra toxicity: Preliminary analysis of 1115 patients in the MRC AML15 trial.

R. Hills, N. Russell, A. Hunter, 2006 .

A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy.

R. Clark, M. Levis, D. Small, 2004 .

A phase 2 trial of the FLT 3 inhibitor lestaurtinib ( CEP 701 ) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy

M. Levis, D. Small, R. Chopra, 2006 .

A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia.

A. Rohatiner, R. Clark, A. Hunter, 2003, Blood.